Vnitr Lek 2019, 65(10):636-642 | DOI: 10.36290/vnl.2019.111

Inflammatory myocardial disease

Jan Krejčí*, Hana Poloczková
I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně

Inflammatory diseases of the heart muscle include myocarditis and inflammatory cardiomyopathy, which is myocarditis associated with a heart muscle dysfunction. The causes of myocardial inflammatory disorders may be infectious, most commonly viral, as well as non-infectious. Diagnosing is difficult, the clinical suspicion of this diagnosis can be established based on clinical picture and non-invasive diagnostic methods, the most important of which is cardiac magnetic resonance imaging. The definitive diagnosis is based on histological and immunohistochemical evidence of inflammation directly from heart muscle samples. These can be obtained by endomyocardial biopsy which is also the gold standard of diagnosis. In addition to the demonstration of inflammatory changes, the examination of biopsy specimens allows for specification of their character and the obtained tissue can also be examined for presence of infectious agents in the myocardium. Based on the findings it is then possible to estimate the prognosis, set the timing of further therapeutic steps (especially device-based therapy) and, in some cases, administer specific treatments.

Keywords: diagnostics; endomyocardial biopsy; immunosuppressive treatment; inflammatory cardiomyopathy; myocarditis

Received: April 1, 2019; Accepted: September 23, 2019; Published: October 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krejčí J, Poloczková H. Inflammatory myocardial disease. Vnitr Lek. 2019;65(10):636-642. doi: 10.36290/vnl.2019.111.
Download citation

References

  1. Caforio ALP, Pankuweit S, Arbustini E et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636-2648, 2648a-2648d. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht210>. Go to original source... Go to PubMed...
  2. Kindermann I, Barth C, Mahfoud F et al. Update on myocarditis. J Am Coll Cardiol 2012; 59(9): 779-792. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2011.09.074>. Go to original source... Go to PubMed...
  3. Cooper LT. Myocarditis. N Engl J Med 2009; 360(15): 1526-1538. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra0800028>. Go to original source... Go to PubMed...
  4. Trachtenberg BH, Hare JM. Inflammatory Cardiomyopathic Syndromes. Circ Res 2017; 121(7): 803-818. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.117.310221>. Go to original source... Go to PubMed...
  5. Lund LH, Edwards LB, Dipchand AI et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indication for Transplant. J Heart Lung Transplant 2016; 35(10): 1158-1169. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2016.08.017>. Go to original source... Go to PubMed...
  6. Heymans S, Eriksson U, Lehtonen J et al. Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. J Am Coll Cardiol 2016; 68(21): 2348-2364. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2016.09.937>. Go to original source... Go to PubMed...
  7. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J 2008; 29(17): 2073-2082. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehn296>. Go to original source... Go to PubMed...
  8. Schultheiss HP, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J 2011; 32(21): 2616-2625.Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehr165>. Go to original source... Go to PubMed...
  9. Krejci J, Mlejnek D, Sochorova D et al. Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment. Biomed Res Int 2016; 2016: 4087632. Dostupné z DOI: <http://dx.doi.org/10.1155/2016/4087632>. Go to original source... Go to PubMed...
  10. Richardson P, McKenna W, Bristow M et al. Report of the 1995 World Health Organisation/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93(5): 841-842. Dostupné z DOI: <http://dx.doi.org/10.1161/01.cir.93.5.841>. Go to original source... Go to PubMed...
  11. Aretz HAT, Billingham ME, Edwards WD et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987; 1(1): 3-14.
  12. Kühl U, Noutsias M, Seeberg B et al. Immunohistological evidence for chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart 1996; 75(3): 295-300. Dostupné z DOI: <http://dx.doi.org/10.1136/hrt.75.3.295>. Go to original source... Go to PubMed...
  13. Maisch B, Portig I, Ristic A et al. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report Herz 2000; 25(3): 200-209. Go to original source... Go to PubMed...
  14. Caforio ALP, Marcolongo R, Basso C et al. Clinical presentation and diagnosis of myocarditis. Heart 2015; 101(16): 1332-1344. Dostupné z DOI: <http://dx.doi.org/10.1136/heartjnl-2014-306363>. Go to original source... Go to PubMed...
  15. Hufnagel G, Pankuweit S, Richter A et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID): first epidemiological results. Herz 2000; 25(3): 279-285. Go to original source... Go to PubMed...
  16. Kühl U, Pauschinger M, Noutsias M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005; 111(7): 887-893. Dostupné z DOI: <http://dx.doi.org/10.1161/01.CIR.0000155616.07901.35>. Go to original source... Go to PubMed...
  17. Krejci J, Poloczkova H, Hude P et al. Impact of inflammatory infiltration and viral genome presence in myocardium on the changes of echocardiographic parameters. Cor et Vasa 2013; 55(4): e333-e340. Dostupné z DOI: <https://doi.org/10.1016/j.crvasa.2013.02.003> Go to original source...
  18. Kuethe F, Lindner J, Matschke K et al. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis 2009; 49(11): 1660-1666. Dostupné z DOI: <http://dx.doi.org/10.1086/648074>. Go to original source... Go to PubMed...
  19. Escher F, Modrow S, Sabi T et al. Parvovirus B19 profiles in patients with acute myocarditis and chronic dilated cardiomyopathy. Med Sci Monit 2008; 14: CR589-CR597.
  20. Verdonschot J, Hazebroek M, Merken J et al. Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature. Eur J Heart Fail 2016; 18(12): 1430-1441. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.665>. Go to original source... Go to PubMed...
  21. Bock CT, Düchting A, Utta F et al. Molecular phenotypes of human parvovirus B19 in patients with myocarditis. World J Cardiol 2014; 6(4): 183-195. Dostupné z DOI: <http://dx.doi.org/10.4330/wjc.v6.i4.183>. Go to original source... Go to PubMed...
  22. Wehlou C, Delanghe JR. Detection of antibodies in cardiac autoimmmunity. Clin Chim Acta 2009; 408(1-2): 114-122. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2009.08.002>. Go to original source... Go to PubMed...
  23. Caforio AL, Mahon NJ, Tona F et al. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 2002; 4(4): 411-417. Dostupné z DOI: <http://dx.doi.org/10.1016/s1388-9842(02)00010-7>. Go to original source... Go to PubMed...
  24. Rose NR. Myocarditis: infection versus autoimmunity. J Clin Immunol 2009; 29(6): 730-737. Dostupné z DOI: <http://dx.doi.org/10.1007/s10875-009-9339-z>. Go to original source... Go to PubMed...
  25. Krejci J, Hude P, Ozábalová E et al. Improvement of left ventricular systolic function in inflammatory cardiomyopathy: What plays a role? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160(4): 524-532. Dostupné z DOI: <http://dx.doi.org/10.5507/bp.2016.033>. Go to original source... Go to PubMed...
  26. Caforio ALP, Calabrese F, Angelini A et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007; 28(11): 1326-1333. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehm076>. Go to original source... Go to PubMed...
  27. Fairweather D, Cooper LT, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol 2013; 38(1): 7-46. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cpcardiol.2012.07.003> Go to original source... Go to PubMed...
  28. D'Ambrosio A, Patti G, Manzoli A et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001; 85(5): 499-504. Dostupné z DOI: <http://dx.doi.org/10.1136/heart.85.5.499>. Go to original source... Go to PubMed...
  29. Krejci J, Hude P, Poloczkova H et al. Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy. Heart Vessels 2016; 31(3): 416-426. Dostupné z DOI: <http://dx.doi.org/10.1007/s00380-014-0618-0>. Go to original source... Go to PubMed...
  30. McCarthy RE, Boehmer JP, Hruban RH et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342(10): 690-695. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200003093421003>. Go to original source... Go to PubMed...
  31. Kandolin R, Lehtonen J, Salmenkivi K et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 2013; 6(1): 15-22. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.969261>. Go to original source... Go to PubMed...
  32. Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev 2013; 18(6): 733-746. Dostupné z DOI: <http://dx.doi.org/10.1007/s10741-012-9358-3>. Go to original source... Go to PubMed...
  33. Baccouche H, Mahrholdt H, Meinhardt G et al. Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease. Eur Heart J 2009; 30(23): 2869-2879. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehp328>. Go to original source... Go to PubMed...
  34. Olimunder MA, van Els J, Galjee MA. The importance of cardiac MRI as a diagnostic tool in viral myocarditis-induced cardiomyopathy. Neth Heart J 2009; 17(2): 481-486. Dostupné z DOI: <http://dx.doi.org/10.1007/bf03086308>. Go to original source... Go to PubMed...
  35. Bruder O, Wagner A, Lombardi M et al. European Cardiovascular Magnetic Resonance (EuroCMR) registry - multinational results from 57 centers in 15 countries. J Cardiovasc Magn Reson 2013; 15: 9. Dostupné z DOI: <http://dx.doi.org/10.1186/1532-429X-15-9>. Go to original source... Go to PubMed...
  36. Lurz P, Eitel I, Adam J et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging 2012; 5(5): 513-524. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2011.11.022>. Go to original source... Go to PubMed...
  37. Kuchynka P, Palecek T, Nemecek E et al. New therapeutic aspects on inflammatory cardiomyopathy. Curr Pharm Des 2015; 21(4): 459-465. Dostupné z DOI: <http://dx.doi.org/10.2174/138161282104141204142244>. Go to original source... Go to PubMed...
  38. Friedrich MG, Sechtem U, Schulz-Menger J et al. Cardiovascular magnetic resonance in myocarditis: a JACC White paper. J Am Coll Cardiol 2009; 53(17): 1475-1487. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2009.02.007>. Go to original source... Go to PubMed...
  39. Grün S, Schumm J, Greulich S et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 2012; 59(18): 1604-1615. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.01.007>. Go to original source... Go to PubMed...
  40. Francone M, Chimenti C, Galea A et al. CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis. JACC Cardiovasc Imaging 2014; 7(3): 254-263. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2013.10.011>. Go to original source... Go to PubMed...
  41. Ferreira VM, Schulz-Menger J, Holmvang G et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol 2018; 72(24): 3158-3176. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2018.09.072>. Go to original source... Go to PubMed...
  42. Mahfoud F, Gärtner B, Kindermann M et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J 2011; 32(7): 897-903. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehq493>. Go to original source... Go to PubMed...
  43. Heidecker B, Kittleson MM, Kasper EK et al. Transcriptomic biomarkers for the accurate diagnosis of myocarditis. Circulation 2011; 123(11): 1174-1184. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.002857>. Go to original source... Go to PubMed...
  44. Cooper LT, Onuma OK, Sagar S et al. Genomic and proteomic analysis of myocarditis and dilated cardiomyopathy. Heart Fail Clin 2010; 6(1): 75-85. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hfc.2009.08.012>. Go to original source... Go to PubMed...
  45. Corsten MF, Papageorgiou A, Verhesen W et al. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ Res 2012; 111(4): 415-425. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.112.267443>. Go to original source... Go to PubMed...
  46. Mason JW, O'Connell JB, Herskowitz A et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333(5): 269-275. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199508033330501>. Go to original source... Go to PubMed...
  47. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009; 30(16): 1995-2002. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehp249>. Go to original source... Go to PubMed...
  48. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C et al. Randomized, placebo controled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Circulation 2001; 104(1): 39-45. Dostupné z DOI: <http://dx.doi.org/10.1161/01.cir.104.1.39>. Go to original source... Go to PubMed...
  49. Lu C, Qin F, Yan Y et al. Immunosuppressive treatment for myocarditis: a meta-analysis of randomized controlled trials. J Cardiovasc Med (Hagerstown) 2016; 17(8): 631-637. Dostupné z DOI: <http://dx.doi.org/10.2459/JCM.0000000000000134>. Go to original source... Go to PubMed...
  50. Merken J, Hazebroek M, Van Paassen P et al. Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy. Circ Heart Fail 2018; 11(2): e004228. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.117.004228>. Go to original source... Go to PubMed...
  51. Kühl U, Lassner D, von Schlippenbach J et al. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol 2012; 60(14): 1295-1296. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.06.026>. Go to original source... Go to PubMed...
  52. Schultheiss HP, Piper C, Sowade O et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 2016; 105(9): 763-773. Dostupné z DOI: <http://dx.doi.org/10.1007/s00392-016-0986-9>. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.